From: Nephrolithiasis in gout: prevalence and characteristics of Brazilian patients
Nephrolithiasis (N = 43) | Without Nephrolithiasis (N = 80) | P Value | |
---|---|---|---|
Male gender | 43 (100%) | 72 (90.0%) | 0.049 |
Skin color/race: white | 37 (86.0%) | 65 (81.2%) | 0.500 |
Age (years) | 61.3 ± 9.7 | 63.8 ± 9.3 | 0.161 |
Age of onset of disease (years) | 42.3 ± 11.4 | 46.4 ± 12.7 | 0.080 |
Duration of disease (years) | 19.0 ± 10.8 | 17.8 ± 10.4 | 0.502 |
< 5 years | 1 (9.1%)* | 10 (90.9%)* | 0.168† |
5–15 years | 19 (38.0%)* | 31 (62.0%)* | – |
> 15 years | 23 (37.1%)* | 39 (62.9%)* | – |
Tophi | 24 (55.8%) | 45 (56.2%) | 0.963 |
Underexcretion of uric acid | 38 (88.4%) | 72 (91.4%) | 0.624 |
Alcohol use disorder | 36 (83.7%) | 54 (67.5%) | 0.053 |
Current | 9 (20.9%) | 14 (17.5%) | 0.642 |
Past | 27 (62.8%) | 40 (50.0%) | 0.174 |
Smoking history | 25 (58.1%) | 38 (47.5%) | 0.260 |
Current | 2 (4.7%) | 8 (10.0%) | 0.491 |
Past | 23 (53.5%) | 30 (37.5%) | 0.088 |
Medication | |||
Allopurinol | 19 (44.2%) | 26 (32.5%) | 0.199 |
Benzbromarone | 21 (48.8%) | 55 (68.8%) | 0.030 |
Potassium citrate | 13 (30.2%) | Zero | < 0.001 |
Colchicine | 15 (34.9%) | 17 (21.2%) | 0.100 |
Glucocorticoids | 2 (4.7%) | 5 (6.2%) | 1.000 |
NSAIDs | 23 (53.5%) | 41 (51.2%) | 0.813 |
Antidiabetic medication | 10 (23.3%) | 8 (10.0%) | 0.047 |
Antihypertensives | 34 (79.1%) | 58 (72.5%) | 0.424 |
Lipid-lowering medication | 15 (34.9%) | 10 (12.5%) | 0.003 |